5-Arylidenethioxothiazolidinones as Inhibitors of Tyrosyl–DNA Phosphodiesterase I

Abstract

Tyrosyl-DNA phosphodiesterase I (Tdp1) is a cellular enzyme that repairs the irreversible topoisomerase I (Top1)-DNA complexes and confers chemotherapeutic resistance to Top1 inhibitors. Inhibiting Tdp1 provides an attractive approach to potentiating clinically used Top1 inhibitors. However, despite recent efforts in studying Tdp1 as a therapeutic target, its inhibition remains poorly understood and largely underexplored. We describe herein the discovery of arylidene thioxothiazolidinone as a scaffold for potent Tdp1 inhibitors based on an initial tyrphostin lead compound 8. Through structure-activity relationship (SAR) studies we demonstrated that arylidene thioxothiazolidinones inhibit Tdp1 and identified compound 50 as a submicromolar inhibitor of Tdp1 (IC₅₀ = 0.87 μM). Molecular modeling provided insight into key interactions essential for observed activities. Some derivatives were also active against endogenous Tdp1 in whole cell extracts. These findings contribute to advancing the understanding on Tdp1 inhibition.

New inhibitors of tyrosyl-DNA phosphodiesterase I (Tdp 1) combining 7-hydroxycoumarin and monoterpenoid moieties

“…90 °C. 11), 2H-C(12)); 2.53 (tm, 2H, J(10,11)=6.2, 2H-C(10)); 2.71 (tm, 2H, J (13,12)=6.2, 2H-C(13)); 5.09 (s, 2H, 2H-C(14)); 6.84 (d, 1H, J(9,7) = 2.5, H-C(9)); 6.88 (dd, 1H, J(7,6)= 8.8, J (7,9) =2.5, H-C(7)); 7.32 (tt, 1H, J (18,17(19))=7.1, J (18,16(20))=1.5, H-C (18) (20)). 13 C-NMR (CDCl 3 , δ C ): 153.31 (s, C(1)); 161.95 (s, C(2)); 120.54 (s, C(3)); 147.05 (s, C(4)); 113.85 (s, C(5)); 124.00 (d, C(6)); 112.46 (d, C(7)); 160.33 (s, C(8)); 101.60 (d, C(9)); 23.71 (t, C(10)); 21.56 (t, C(11)); 21.26 (t, C(12)); 25.08 (t, C(13)); 70.24 (t, C(14)); 135.93 (s, C(15)); 127.…”

“…36 4, H-C(9)); 6.81 (dd, 1H, J(7,6)=8.7, J (7,9)=2.4, H-C(7)); 7.40 (d, 1H, J(6,7)=8.7, H-C(6)). 13 C-NMR (CDCl 3 , δ C ): 153.30 (s, C(1)); 162.12 (s, C(2)); 120.29 (s, C(3)); 147.17 (s, C(4)); 113.54 (s, C(5)); 123.79 (d, C(6)); 112.62 (d, C(7)); 160.69 (s, C(8)); 101.49 (d, C(9)); 23.72 (t, C(10)); 21.60 (t, C(11)); 21.29 (t, C(12)); 25.10 (t, C(13)); 70.93 (t, C(14)); 143.12 (s, C(15)); 121.12 (d, C (16) 16), H-C(20)); 6.85 (d, 1H, J(9,7)=2.5, H-C(9)); 6.89 (dd, 1H, J(7,6)=8.8, J (7,9)=2.5, H-C(7)); 7.44 (d, 1H, J(6,7)=8.8, H-C(6)). 13 C-NMR (CDCl 3 , δ C ): 153.32 (s, C(1)); 162.00 (s, C(2)); 120.64 (s, C(3)); 147.12 (s, C(4));113.95 (s, C(5)); 124.05 (d, C(6)); 112.50 (d, C(7)); 160.27 (s, C(8)); 101.54 (d, C(9)); 23.72 (t, C(10)); 21.55 (t, C(11)); 21.26 (t, C(12)); 25.11 (t, C(13)); 70.53 (t, C (14) 17)); 6.75 (d, 1H, J(9,7)=2.5, H-C(9)); 6.79 (dd, 1H, J(7,6)=8.8, J (7,9)=2.5, H-C(7)); 7.41 (d, 1H, J(6,7)=8.8, H-C(6)).…”

“…13 C-NMR (CDCl 3 , δ C ): 153.30 (s, C(1)); 162.12 (s, C(2)); 120.29 (s, C(3)); 147.17 (s, C(4)); 113.54 (s, C(5)); 123.79 (d, C(6)); 112.62 (d, C(7)); 160.69 (s, C(8)); 101.49 (d, C(9)); 23.72 (t, C(10)); 21.60 (t, C(11)); 21.29 (t, C(12)); 25.10 (t, C(13)); 70.93 (t, C(14)); 143.12 (s, C(15)); 121.12 (d, C (16) 16), H-C(20)); 6.85 (d, 1H, J(9,7)=2.5, H-C(9)); 6.89 (dd, 1H, J(7,6)=8.8, J (7,9)=2.5, H-C(7)); 7.44 (d, 1H, J(6,7)=8.8, H-C(6)). 13 C-NMR (CDCl 3 , δ C ): 153.32 (s, C(1)); 162.00 (s, C(2)); 120.64 (s, C(3)); 147.12 (s, C(4));113.95 (s, C(5)); 124.05 (d, C(6)); 112.50 (d, C(7)); 160.27 (s, C(8)); 101.54 (d, C(9)); 23.72 (t, C(10)); 21.55 (t, C(11)); 21.26 (t, C(12)); 25.11 (t, C(13)); 70.53 (t, C (14) 17)); 6.75 (d, 1H, J(9,7)=2.5, H-C(9)); 6.79 (dd, 1H, J(7,6)=8.8, J (7,9)=2.5, H-C(7)); 7.41 (d, 1H, J(6,7)=8.8, H-C(6)). 13 C-NMR (CDCl 3 , δ C ): 153.36 (s, C(1)); 162.12 (s, C(2)); 120.24 (s, C(3)); 147.24 (s, C(4)); 113.49 (c, C(5)); 123.93 (d, C(6)); 112.32 (d, C(7)); 160.64 (s, C(8)); 100.94 (d, C(9)); 23.69 (t, C(10)); 21.27 (t, C(11)); 21.58 (t, C(12)); 25.10 (t, C(13); 66.68 (t, C(14)); 36.11 (t, C(15)); 143.95 (s, C(16)); 118.89 (d, C (17) (7,9)=2.5, H-C(7)); 6.90 (d, 1H, J(9,7)=2.5, H-C(9)); 6.95 (dd, 1H, J (15,17)=2.6, J (15,19)=1.6, H-C(15)); 6.98 (ddd, 1H, J (19,18)=7.6, J (19,15)=1.6, J (19,17)=1.0, H-C(19)); 7.29 (dd, 1H, J (18,17)=8.3, J (18,19)=7.…”

“…6, H-C(18)); 7.32 (d, 1H, J(6,7)=9.2, H-C(6)). 13 C-NMR (CDCl 3 , δ C ): 155.60 (s, C(1)); 160.32 (s, C(2)); 124.57 (s, C(3)); 156.10 (s, C(4)); 112.55 (s, C(5)); 125.49 (d, C(6)); 112.70 (d, C(7)); 160.89 (s, C(8)); 101.81 (d, C(9)); 30.26 (t, C(10)); 22.45 (t, C(11)); 31.93 (t, C(12)); 70.19 (t, C(13)); 137.45 (s, C(14)); 112.85 (d, C(15)); 159.83 (s, C(16)); 113.62 (d, C (17) 15)), 6.82 (dd, 1H, J(7,6)=8.6, J (7,9)=2.4, H-C(7)); 6.85 (d, 1H, J(9,7)=2.4, H-C(9)); 7.29 (d, 1H, J(6,7)=8.6, H-C(6)). 13 C-NMR (CDCl 3 , δ C ): 155.60 (s, C(1)); 160.48 (s, C(2)); 124.28 (s, C(3)); 156.23 (s, C(4)); 112.21 (s, C(5)); 125.28 (d, C(6)); 112.85 (d, C(7)); 161.29 (s, C(8)); 101.67 (d, C(9)); 30.24 (t, C(10)); 22.47 (t, C(11)); 31.93 (t, C(12)); 71.00 (t, C(13)); 143.07 (s, C (14) 6)).…”

BMI-1 is important in bufalin-induced apoptosis of K562 cells

“…Inhibiting Tdp1 provides an attractive approach to potentiating clinically used Top1 inhibitors (66,67). Bufalin is able to reduce the quantity, activity and mRNA levels of topoisomerase II (11).…”